Mr-024. Survival Outcomes And Prognostic Considerations Of Stereotactic Radiosurgery In The Treatment Of Recurrent Malignant Gliomas With And Without Bevacizumab
2013
INTRODUCTION: Stereotactic radiosurgery (SRS) has not proven beneficial in the management of newly diagnosed malignant gliomas (MG), but is used for salvage. Bevacizumab may give an additional benefit to SRS. METHODS: We analyzed 40 consecutive patients treated with SRS alone or with bevacizumab for progressive enhancing lesions. Dose was 25 Gy in 5 fractions over a week. We assessed overall survival from SRS(OS), progression free survival from SRS(PFS), age, gender, lesion volume and location, dexamethasone use, pre-SRS chemotherapeutic and surgical interventions, and bevacizumab use. RESULTS: Initial diagnosis was glioblastoma (GBM) in 25, gliomatosis cerebri 1, anaplastic astrocytomas(AA) 2, oligodendromas(OD) 6, anaplastic oligodendromas(AO) 4, anaplastic oligoastrocytomas(AOA) 1, and epithelial ependyoma(EE) 1. Six-month PFS and twelve-month OS were 51.4% and 48.7%. Median PFS and OS were 5.51 and 12.27 months (m). GBM and AA had OS of 9.5m compared to 28.5m for OD, AOD, and EE (p 40 (p = 0.226). OS was 15.2m for males versus 9.5m for females (p = 0.0612). Frontal and temporal lobe recurrences had OS of 13.1m and 12.3m while parietal and thalamic lesions showed OS of 9.2m and 8.7m. OS was 18.7m for tumor volumes 10cc (p
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI